STOCK TITAN

Zentalis Pharmaceuticals Inc - ZNTL STOCK NEWS

Welcome to our dedicated news page for Zentalis Pharmaceuticals (Ticker: ZNTL), a resource for investors and traders seeking the latest updates and insights on Zentalis Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Zentalis Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Zentalis Pharmaceuticals's position in the market.

Rhea-AI Summary
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) granted 42,000 stock options and 28,000 restricted stock units to a newly hired employee under the 2022 Inducement Plan. The options have an exercise price of $11.34 per share, a 10-year term, and will vest over four years, while the restricted stock units will also vest over four years. Vesting is subject to the employee's continued service to Zentalis on each vesting date.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) to hold investor call and participate in fireside chat at Jefferies London Healthcare Conference. CEO and CFO to discuss azenosertib ovarian cancer clinical updates with key opinion leader on November 10th, 2023. Live webcasts and archived recordings available on company website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.3%
Tags
conferences
-
Rhea-AI Summary
Zentalis Pharmaceuticals, Inc. announced updated data from a study of azenosertib monotherapy, showing an objective response rate (ORR) of 37% and a median progression-free survival (mPFS) of 6.5 months in ovarian and uterine serous carcinoma patients. The company plans to submit the first New Drug Application (NDA) for azenosertib in a gynecologic malignancy in 2026. They also highlighted their cash balance of $517 million as of September 30, 2023, and the appointment of Mark Lackner, Ph.D., as the new Chief Scientific Officer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-30.2%
Tags
Rhea-AI Summary
Zentalis Pharmaceuticals has granted non-qualified stock options to five newly hired employees. The options allow the purchase of 271,000 shares of the company's common stock. The options have an exercise price of $16.35 per share and a 10-year term. They will vest over four years, with 25% vesting on the first anniversary and the remaining 75% vesting in equal monthly installments over the next three years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.53%
Tags
none
-
Rhea-AI Summary
Zentalis Pharmaceuticals grants stock options to new employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.77%
Tags
none
-
Rhea-AI Summary
Zentalis Pharmaceuticals CEO to participate in fireside chat at Morgan Stanley Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.51%
Tags
conferences
Rhea-AI Summary
Zentalis Pharmaceuticals grants stock options to new employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) announced positive Phase 1b data for azenosertib monotherapy and azenosertib + chemotherapy combinations in ovarian cancer patients. The company raised $250.0 million from a recent offering, extending cash runway into 2026. The program highlights the identified monotherapy recommended Phase 2 dose, positive safety and efficacy data, and biomarker enrichment strategies. Corporate highlights include new appointments and a public offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.71%
Tags
-
Rhea-AI Summary
Zentalis Pharmaceuticals, Inc. (ZNTL) announced the granting of 275,000 non-qualified stock options to a newly hired employee under the 2022 Inducement Plan. The options have an exercise price of $26.25 per share, a 10-year term, and will vest over four years, subject to the employee's continued service to the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.53%
Tags
none
Rhea-AI Summary
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) appoints Kimberly Freeman as Chief Strategy Officer, leveraging her 25 years of clinical development and strategic leadership experience, particularly in gynecologic malignancies and the DNA damage response pathway. She will support Zentalis' long-term portfolio strategy, focusing on advancing azenosertib to patients with ovarian and uterine cancers, and other Cyclin E1 positive tumor types where patients typically face poor prognosis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.72%
Tags
management
Zentalis Pharmaceuticals Inc

Nasdaq:ZNTL

ZNTL Rankings

ZNTL Stock Data

951.58M
50.35M
4.22%
114.97%
21.88%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
New York

About ZNTL

developing potentially best-in-class, novel small molecules targeting fundamental biological pathways in cancer